CTOs on the Move

Shared Health Services

www.sharedhealthservices.com

 
Shared Health Services is a wound care management company that contracts with hospitals to help them open and manage successful outpatient wound care and hyperbaric centers. The mission of our Wound Care Centers is to heal chronic wounds, improve patient outcomes, help prevent limb loss and provide a profitable service for our contracted hospitals.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

ATRIO Health Plans

ATRIO Health Plans is a Medicare Advantage (MA) plan that offers Preferred Provider Organization (PPO) options, as well as a Health Maintenance Organization (HMO) Special Needs Plans for Dual Eligibles. The health plan is supported by the trusted physicians, who care for individuals and families in the Oregon counties of Douglas, Josephine, Klamath, Marion and Polk.

Children's Medical Center

Children's Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dayton, OH. To find more information about Children's Medical Center, please visit www.childrensdayton.org

Wolters Kluwer Health

Wolters Kluwer Health is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centro Latino de Chelsea

Centro Latino de Chelsea is a Chelsea, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.